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ABSTRACT 
The aim of this study was to develop transdermal patch of Atomoxetine hydrochloride which has good mechanical properties. The transdermal 
patches were preapared used solvent casting method. Different groups of films with drug were prepared using different amalgamations of 
polymers such as HPMC (various grades), Polyox303, Eudragit RL 100.Considering solubility of drug and polymer, the solvent system of water: 
ethanol was chosen.In-vitro release of drug substance was performed  using phosphate buffer solution (PBS) pH 7.4. Compatibility of drug with 
different excipient (drug: excipient in the ratio 1:1) was carried out using Fourier Transform Infra-Red Spectroscopy (FTIR). Evaluation test 
such as weight variation, content uniformity, drug content, folding endurance, thickness, in-vitro dissolution and in-vitro disintegration were 
done. The folding endurance of the all batches found less than 500 times.The percentages of drug distribution was found in between 72 to 
100%.The formulation F4 containing a combination of HPMC and Eudragit showed maximum drug release of 95.26%. The method employed to 
prepare patches was capable of producing patches with almost uniform drug distribution. Stability studies were conducted as per ICH guidlines 
(40±2○C at 75±5% RH) for optimized formulations and was found to be stable. 
Keywords: Atomoxetine hydrochloride, Transdermal Patch  
 
Article Info: Received 25 Feb 2019;     Review Completed 30 March 2019;     Accepted 21 April 2019;     Available online 25 April 2019 
Cite this article as: 
Kulkarni S, Formulation and Evaluation of Transdermal Patch for Atomoxetine hydrochloride, Journal of Drug Delivery 
and Therapeutics. 2019; 9(2-A):32-35      
*Address for Correspondence:  
Sweta Kulkarni, Assistant Professor, Chameli Devi Institute of Pharmacy, Indore, M.P., India 
 
 
INTRODUCTION 
Transdermal drug delivery system (TDDS) is one of the 
systems lying under the category of controlled drug delivery, 
in which the aim is to deliver the drug through the skin in a 
predetermined and controlled rate. TDDS are adhesive drug-
containing devices of defined surface area that deliver a 
predetermined amount of drug to the surface of intact skin at 
a programmed rate to reach the systemic circulation 1,2 . 
The novel drug delivery system also be beneficial in the 
industry for improving the solubility, stability and biological 
half life of the drugs. The robustness of the strip depends on 
the type of polymer used in the formulation3. Drugs which 
are prone to considerable first pass metabolism or degraded 
in acidic environment of stomach are poorly absorbed from 
the GIT or when the therapy demands rapid onset of action, 
then transdermal route is used 4. 
The precise mechanism by which Atomoxetine produces its 
therapeutic effects in Attention-Deficit/Hyperactivity 
Disorder (ADHD) is unknown, but is thought to be related to 
selective inhibition of the pre-synaptic norepinephrine 
transporter, as determined in ex vivo uptake and 
neurotransmitter depletion studies. The drug is used for the 
treatment of Attention deficit hyperactivity disorder (ADHD) 
and also in antidepressant. Attention-deficit/hyperactivity 
disorder (ADHD) is a common psychological diagnosis in 
children4. 
 It Belongs to BCS class 1, and it undergoes first pass 
metabolism. Atomoxetine HCl appears to have minimal 
affinity for other noradrenergic receptors. And drug is 
rapidly absorbed after oral administration, So the drug is 
used in transdermal formulation5. 
The objective of this work was to prepare transdermal patch 
of Atomoxetine HCl which has good mechanical properties 
and evaluate the patch for its appearance, weight uniformity, 
drug content, drug release, tensile strength, folding 
endurance, thickness and stability7. 
MATERIAL AND METHODS 
Atomoxetine hydrochloride was obtained as gift sample from 
Mann Medix Pharma ltd, and all the excipients from loba 
chemicals, Mumbai 
 Preparation of medicated films: 
The polymer was dissolve in 20ml methanol and water 
solution in beaker A. In B beaker 10ml ethanol, water, 
polyethylene glycol 400 was dissolve. And in a vial take a 
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propylene glycol were taken and dissolve the drug by using 
ultrasonicater. Mix solution A into B. and solution in vial with 
the help of mechanical stirrer for 2-3 hrs. 
Preparation of non-sticky petri plate: 
The silicon emulsion was used used to prepare the non-
sticky petri plates for casting of plates. Firstly the silicon 
emulsion was poured and spread with the thumb. The plates 
were then kept in oven for 12 hours at 120 0c. The dried 
plates were used to cast the films. Petri plate had diameter of 
9.6 cm. 
Casting and drying of films: 
Above mixture was poured in petri plates which were 
pretreated with silicon emulsion. The petri plates were kept 
in closed box with inverted funnel for the controlled 
evaporation of organic solvents used. The controlled 
evaporation is required for uniform drying of films. The 
drying was carried out at room temperature for at least 24 
hours. Then the films were cut into small patches of 2cm 
×2cm
 
Table 1: Formula of medicated patches 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 
HPMC K15 - - - - - - - - 
HPMC E 50 500mg - - - 400mg 350mg - 450mg 
HPMC E 15 - - - 400mg - - 400mg - 
Eudragit RL 100 - 500mg - 50mg - - - 50mg 
Polyox 303 - - - - 100mg 50mg 100mg - 
HPMCK 100 - - 500 - - - - - 
PEG 400 150mg 150mg 150mg 150mg 150mg 150mg 150mg 150mg 
Propylene glycol 0.8ml 0.8ml 0.8ml 0.8ml 0.8ml 0.8ml 0.8ml 0.8ml 
Atomoxetine  HCL 177mg 177mg 177mg 177mg 177mg 177mg 177mg 177mg 
Water: ethanol(1:2) 30ml 30ml 30ml 30ml 30ml 30ml 30ml 30ml 
 
Method for Evaluation of Patches 
Physicochemical evaluations of oral films  
Films were evaluated for their visual inspection or film 
formation, weight variation, folding endurance, Drug 
content, thickness test, In-vitro dissolution. 
Visual inspection and appearance  
The films were evaluated visually for its clarity, 
transparency and stickiness. Films that were satisfactory 
were evaluated further and if they were unsatisfactory they 
were discarded. 
IR Spectrum 6 
IR absorption spectrum of Atomoxetine  HCl was recorded 
by potassium bromide dispersion technique in which dry 
samples and potassium bromide were placed in sample 
holder and infrared spectrum was recorded using FTIR 
spectrophotometer. 
Determination of λ max 6 
 10 mg of Atomoxetine HCLwas accurately weighed and was 
dissolved in 100 ml methanol to get 100 μg/ml solution. UV 
spectrum was recorded in wavelength range of 200-400nm. 
Weight variation 7 
The patches were subjected to weight variation by 
individually weighing five different randomly selected 
patches. Such determination was carried out for each 
formulation. 
The test ensures the uniformity of the formed film. From the 
whole film three small pieces, each of 2×2 cm2 area and were 
weighed individually. The standard deviation from the mean 
value was reported 
Water vapour transmission rate: 7 
1 gm. of fused calcium chloride as dessicant was taken in 
vials and polymeric patch fixed over vial by adhesive tape. 
Weight the vial and put it in to the humidity chamber at an 
RH 80% and temp at 300c. Then the vial for taken out 
periodically and weighed.  
 
Folding endurance 8  
This was determined by repeatedly folding the film at the 
same place until it broke. The number of times the films 
could be folded at the same place without breaking/cracking 
gave the value of folding endurance. 
Folding endurance was determined by repeatedly folding a 
small strip of the film at the same place until it breaks. The 
number of times the film is folded at specific place without 
breaking gives the folding endurance. 
Thickness of film 8 
Appearances of the films were checked for uniformity and 
for the presence of air bubbles. Thickness of the randomly 
selected films was determined using Vernier callipers from 
every batch and the average values were determined. 
The thickness of patches was measured at five different 
places using a Vernier caliper with least count 0.01mm and 
mean values were calculated. 
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Tensile strength 9 
The tensile strength was determined by the tensile strength 
apparatus and the tensile strength was calculated by using 
following formula 
 
where, S = tensile stress in 980 dynes/cm2 
 m = mass in grams 
g = acceleration due to gravity (980 dynes/cm2) 
b = breadth of strip in centimeters 
t = thickness of strip in centimeters 
In vitro dissolution 10 
Phosphate buffer pH 7.4 was used as the dissolution medium 
to determine the in vitro dissolution study. The temperature 
was maintained at 37±0.5°C with a stirring rate of 100 rpm. 
Samples were withdrawn at 0, 1, 3, 5, 10 intervals and then 
replaced by equal volumes of medium. The withdrawn 
samples were analysed by UV Visible spectrophotometer 
Stability study 10 
Stability studies are conducted according to theICH 
guidelines at 40°C and 75% RH .The samples are analyzed 
for the drug content. 
RESULT AND DISCUSSION 
Visual Appearance: 
All the formulations were visually transparent, thin and 
smooth . Some of the polymers are used alone and some of 
them are used in combinations .The films which are formed 
with good appearance and smooth are used for further 
evaluations. 
FTIR studies: 
The IR spectra of pure Atomoxetine HCl showed peaks at 
3195.15, 3395.76,1629.90, 2630.99, 732.97 for C-CH stretch 
, N-H stretch, N-H stretch (Secondary amine), N-H stretch, C-
O stretch. 
UV spectroscopic studies: 
The UV absorption data at 272.5nm and concentration 
estimates of pure Atomoxetine HCL showed good linearity 
(r2-0.9964) over the concentration range of 1-10 µg/ml. 
Hence the given sample of pure Atomoxetine HCl was found 
to obey Beer-Lambert’s law over this range.  
Thickness of the film: 
The thickness of film were found in range of 0.8 to0.25 mm, 
means uniform thickness was found in all the batches. 
Folding endurance: 
The folding endurance of the all batches was found to be less 
than 500 times. Films did not show any cracks even after 
folding upto 500 times which showed a good flexibility of 
patches. 
Weight Variation: 
Uniform weight was found to be   in single polymer batches 
and also in combination batches. The range of weight 
variation was found in between 45.7 to 71.5 mg, means 
uniform weight was found. 
Drug content:  
The result shows that the method employed to prepare 
patches was capable of producing patches with almost 
uniform drug distribution. The percentages of drug 
distribution was found in between 72 to 100% 
The water vapour transmission rate: 
Water vapour transmission through the different patch 
formulations prepared by HPMC and Eudragit RL 100 in 
different ratios. The water vapour transmission rate was 
found in range of 0.0625 to 2.70gm/cm2, and this is higher 
value. 
Tensile strength: 
Tensile strength ranging from 2.4 to 5.9 dynes/cm2,as the 
polymer concentration increase slightly increase in tensile 
strength. 
Drug release of medicated films: 
Average cumulative present release from (F1,F2,F3,F4, 
F5,F6,F7,F8) containing  mg polymer concentration was 
different from each other. They give the 72.42%, 57.46%, 
78.49%, 95.26%, 93.06%, 86.36%, 69.29% and 94.01% 
release. 
  
 
Figure 1: Average cumulative present release from (F1,F2,F3,F4,F5,F6,F7,F8) 
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Stability study: 
Stability study where performed on film obtained with 
formulation F4 and F8 for 2 months at different storages 
conditionas per ICH guidelines.From the result it was found 
that no major changes in values of drug content and drug 
diffusion. It means that formulations are stable in different 
temp. 
 
Table 2: Evaluation of drug loaded patch Evaluation of drug loaded patch [Thickness, Folding Endurance, Water 
vapour transmission rate, Tensile strength] 
FC Thickness 
Folding 
endurance 
Weight 
variation(mg) 
Water vapour 
transmission 
rate (gm/cm2) 
Tensile 
strength 
(dynes/cm2) 
% Drug release 
F1 0.08mm 438 58.4 0.135 3.4 72.42±1.99% 
F2 0.12mm 480 45.7 0.142 4.5 87.46±1.44% 
F3 0.12mm 390 47.9 0.114 2.4 78.49±0.56% 
F4 0.12mm 487 47.4 0.197 3.4 95.26±2.10% 
F5 0.16mm 388 49.1 0.201 3.8 93.06±0.38% 
F6 0.16mm 470 48.3 0.132 3.4 86.36±0.46% 
F7 0.08mm 370 72.6 1.140 3.9 69.29±0.84% 
F8 0.13mm 388 64.5 0.112 4.5 94.01±0.55% 
FC: Formulation Code 
 
CONCLUSION 
Atomoxetine HCl was successfully formulated as 
transdermal patch. Drug excipient compatibility concluded 
that the drug and excipient were compatible with each other. 
Transdermal patches were prepared by using polymers like 
HPMC E 50, HPMC K 15M HPMC K 100,HPMC E 15, chitosan, 
and various combinations of HPMC E 50,  Polyox 303 
,Eudragit RL 100. Considering solubility of drug and 
polymer, the solvent system of water: ethanol was chosen. 
Polyethylene glycol 400(PEG 400) was used as a plasticizer. 
All the films were evaluated for physical and mechanical 
properties like thickness, weight variation, moisture uptake, 
tensile strength, and evaluations like drug content, weight 
variation and in vitro drug release and the values were 
found to be within the acceptable limits. The formulation F4 
containing HMPC E15 and Eudragit showed  a good 
mechanical and physicochemical properties was selected as 
a suitable formulation for further studies. 
The method employed to prepare transdermal patches was 
capable of producing patches with almost uniform drug 
distribution. The optimized formulations were found to be 
stable as per ICH guidelines. However Pharmacokinetic 
studies are needed to be performed to confirm the results of 
this study.   
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